Autonomix Reports Long-Term Pain Relief And Opioid-Free Outcomes In Pancreatic Cancer Trial

Autonomix Medical, Inc. announced new longer-term post hoc results from its first-in-human proof-of-concept (PoC 1) trial assessing the safety and effectiveness of its nerve-targeted transvascular energy delivery technology for severe pancreatic cancer pain. Findings showed rapid and sustained pain relief, with statistically significant reductions observed within 24 hours and lasting up to five months post-procedure.

“These longer-term data build on the compelling results from PoC 1 and appear to show the sustained benefit our technology can deliver to patients with severe cancer pain. Importantly, 100 percent of responders were opioid-free three months post-procedure, reinforcing the potential of our approach as a non-opioid alternative for a highly opioid-dependent population. The durability of effect and quality-of-life improvements further support the value proposition of our platform as we expand into additional visceral cancer pain indications in PoC 2 and beyond,” commented Brad Hauser, CEO of Autonomix.

Detailed analysis highlighted meaningful clinical outcomes among responding patients. On average, participants reported a 65.6% reduction in pain on the VAS scale, with scores dropping from 7.75 at baseline to 2.67 post-treatment. Importantly, 100% of responding patients were opioid-free at three months, suggesting the therapy could offer a much-needed non-opioid alternative for managing cancer-related pain. Additionally, patients experienced notable improvements in global health (76.5%), functional ability (51.5%), and symptom management (50.4%), pointing to better quality of life alongside pain relief.

Encouraged by PoC 1 results, Autonomix has launched a PoC 2 trial aimed at expanding its platform beyond pancreatic cancer pain to other visceral cancers, including gall bladder, liver, and bile duct cancers, as well as earlier-stage pancreatic cancers with moderate to severe pain. The company believes its technology has broad potential across multiple therapeutic areas, with applications in oncology, cardiology, hypertension, and chronic pain management.